

Dreadful Rise of Mucormycosis in Diabetic Patients during Covid Era – A Case Series Analyzing Various Aspects

¹Jeremiah Schmid, Department of Primary Dental Care, University of Minnesota School of Dentistry, 515 Delaware St SE, Minneapolis, MN 55455, USA

Correspondence Author: Jeremiah Schmid, Department of Primary Dental Care, University of Minnesota School of Dentistry, 515 Delaware St SE, Minneapolis, MN 55455, USA

How to Cite This Article: Jeremiah Schmid, “Dreadful Rise of Mucormycosis in Diabetic Patients during Covid Era – A Case Series Analyzing Various Aspects”, IJDSDR – September – October - 2022, Vol. – 1, Issue - 1, P. No. 26 – 29.

Open Access Article: This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

Type of Publication: Case Report

Conflicts of Interest: Nil

Abstract

Novel corona virus infection has been sweeping across the globe since 2019. Various clinical manifestations are seen in coronavirus disease 2019 (COVID-19) patients and there has been a notable rise in the incidence of invasive fungal infections like mucormycosis. The prevalence of mucormycosis is being approximately 0.14 cases per 1000 population which is about 80 times the prevalence in developed countries. Conditions causing immunosuppression are closely associated with the development of any fungal infection including mucormycosis, the most important risk factor for developing mucormycosis is diabetes mellitus. Since mucormycosis lacks stereotypical clinical features, it may show resemblances to other diseases affecting bones and the oral mucosa and early diagnosis is crucial as the infection is rapidly progressive and fatal. The mortality of this infection remains high ranging from 32

to 70% and one of the patient mentioned in this case series died within 2 weeks after diagnosing mucormycosis. Here we are reporting 3 cases of mucormycosis in diabetic patients reported during COVID-19 outbreak.

Keywords: COVID-19, Diabetes Mellitus, Fungal infections, Maxillary sinus, Mucormycosis.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections was first reported in Wuhan (China) and was announced by the World Health Organization in December 2019. Records shows more than 386 million people are affected worldwide and as of February 2022, 5.7 million people have lost their lives.

Patients with COVID-19 are more vulnerable to fungal infection because of the compromised immune system with low CD4 and CD8 lymphocytes, associated conditions like diabetes mellitus and the use of

immunosuppressive agents like steroids for the management in moderate to severe cases. The country has recorded 28,252 cases of mucormycosis from 28 states as of June 7, 2021 and 17,601 cases had diabetes mellitus history and 24,370 cases had history of COVID-19³. A meta-analysis involving 52,916 COVID-19 patients showed that COVID associated mucormycosis incidence is 50 times higher (7 cases per 1000 patients) compared to highest known incidence of mucormycosis cases (0.14 cases per 1000 patients). In this case series we discuss the various aspects of increased incidence of mucormycosis in diabetic patients during COVID-19 era.

Case 1

A 45 year old male patient presented with pain in right upper back tooth region since 20 days. He was a known case of diabetes mellitus. Patient had COVID-19 infection 1 month back and was under medication for the same. On physical examination, there is mild diffuse swelling in the right side of face extending from infraorbital region to lower third of face. Patient's right eye had proptosis with orbital cellulitis. Crustations were present on right nostril and nasal cavity appeared reddish. On palpation tenderness was present in relation to right maxillary region. Intraorally, an ulcerative lesion covered with yellowish slough present in relation to right side of palate. Lesion involved adjacent vestibule and exposed underlying bone.

NCCT PNS showed mucosal thickening of right frontal sinus, bilateral maxillary sinuses, sphenoidal sinus and bilateral ethmoidal sinuses with obliteration of bilateral osteomeatal complex. There is thinning and focal erosion of floor of left maxillary sinus.

Operative procedure included endoscopic debridement of osteomeatal complex and bilateral maxillary sinus debridement.

Case 2

A 70 year old male patient presented with head ache and pain on left side of the face since 5 days. He was a known case of diabetes mellitus and hypertension and was under medication for the same since last 3 years. He had fever 10 days back and tested positive for COVID-19. On extra oral examination diffuse swelling was seen on the left side of the face involving nose. Orbital cellulitis was also seen on the same side. Nasal cavity appeared reddish and few erythematous spot were observed on the lower lip. On intraoral examination ulcerative lesion was observed on the middle third of the palate and upper lip. Edematous and erythematous gingiva seen in relation to 26, 27 and these teeth were tender on percussion.

Nasal endoscopy showed grade 1 changes in right side and grade 2 changes in left side of nasomeatal complex. Screening sinus CT of paranasal sinuses showed polypoidal mucosa thickening in bilateral maxillary, sphenoidal, ethmoid and frontal sinus. Erosion seen in posterior wall of maxillary sinus with preantrol, postantrol, pterygopalatine fissure soft tissue. Nasal septum was deviated to left side with compensatory inferior turbinate hypertrophy.

Surgical management included endoscopic debridement of nasal cavity and maxillary sinus debridement.

Case 3

A 49 year old female patient presented with numbness over the left side of face since 12 days. She was a known case of diabetes mellitus and was under medication for last 6 years. Patient had COVID-19 infection and pneumonia 1 year back. On clinical examination patient was having diffuse swelling in the left side of face with facial palsy and was unable to open left eye. [Figure - 3A] Intraorally ulcerative lesion covered with white

slough seen on left side of palate. Tenderness on percussion present in relation to 23, 24, 25, 26, 27.

MRI paranasal sinus (contrast) showed thickening in left maxillary and ethmoidal sinuses with pre antral and post antral fat stranding. On contrast there is enhancement in the pre antral region in the pterygopalatine fossa and infratemporal fossa with mild bulky pterygoid muscle on left side. On contrast administration there is multifocal non enhancing areas in the left maxillary sinus. Surgical management included left maxillary sinus debridement and left orbital exenteration.

Discussion

Mucormycosis are fatal fungal infections commonly seen in immunocompromised conditions. Diabetes is the single most important risk factor for developing mucormycosis in India in contrast to the developed countries, where hematological malignancies predominate. During this covid outbreak period, patients with moderate to severe COVID-19 are more susceptible to mucormycosis. There is always immunosuppression in Covid-19 patients with a decrease in CD4+ T and CD8+ T cells and there is higher chance of developing fungal co-infections in critically ill patients, like the patients who needs mechanical ventilation, or had a longer duration of hospital stays. In all the cases reported above, patients had diabetes mellitus and severe COVID-19 infection and it is the possible cause of immunosuppression.

Mucormycosis of the sinuses is characterized by initial involvement of the paranasal sinuses and turbinates. During this stage, it will be difficult to distinguish symptoms from those of more common causes of sinusitis. On examination, the nasal mucosa appears initially erythematous, then dark purple and black with the onset of tissue necrosis. In the cases discussed above, 2 patients showed reddish nasal mucosa and one patient

was presented with crustations around nostrils. Other clinical features are facial pain with swelling, epistaxis, headache, proptosis and orbital cellulites, ophthalmoplegia with blindness, hemiplegia or stroke, and decreased mental function. In all the cases discussed, headache and facial edema were commonest clinical finding and one of the patients was presented with orbital complications including complete loss of vision in left eye and underwent orbital exenteration.

Mucormycosis of sinus is seen as nonspecific nodular mucosal thickening on magnetic resonance imaging (MRI) and computed tomography (CT) and this finding was observed in all the cases discussed above. The “black turbinate” sign on contrast MRI may be helpful in differentiating mucormycosis from bacterial sinusitis. Treatment recommendations of mucormycosis were recently updated by the European Confederation of Medical Mycology (ECMM). The first-line drug in mucormycosis therapy is Liposomal Amphotericin B. Isavuconazole (ISZ) and new posaconazole (PSZ) formulations have been added to the guidelines but in second-line treatment following liposomal Amphotericin B (L-AmB) due to some remaining issues.

The prognosis of the infection is poor with the overall mortality ranging between 33.3 and 80% and one of the patient mentioned in this series died within 2 weeks after diagnosing mucormycosis.

Conclusion

There is exponential rise of mucormycosis cases during this covid period. Early diagnosis is very important as the infection is a rapidly progressive fatal in nature. Like any other fungal infection, conditions which cause immunosuppression are closely associated with the rise of mucormycosis. As diabetes mellitus is a common condition causing immunosuppression, there is high chance of developing mucormycosis infection in these

patients. As steroids are integral part of coronavirus disease 2019 (COVID-19) patients treatment, all patients should be monitored closely for sequelae of immunosuppression for months following treatment.

References

1. Azhar A, Khan WH, Khan PA, Alhosaini K, Owais M, Ahmad A. Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach. *J Infect Public Health* [Internet]. 2022 Feb 18 [cited 2022 Mar 22]; Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855610/>
2. Singh R, Kang A, Luo X, Jeyanathan M, Gillgrass A, Afkhami S, et al. COVID-19: Current knowledge in clinical features, immunological responses, and vaccine development. *FASEB J*. 2021 Mar;35(3):e21409.
3. Mahalaxmi I, Jayaramayya K, Venkatesan D, Subramaniam MD, Renu K, Vijayakumar P, et al. Mucormycosis: An opportunistic pathogen during COVID-19. *Environ Res*. 2021 Oct;201:111643.
4. Hussain S, Riad A, Singh A, Klugarová J, Antony B, Banna H, et al. Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis. *J Fungi (Basel)*. 2021 Nov 18;7(11):985.
5. Brunet K, Rammaert B. Mucormycosis treatment: Recommendations, latest advances, and perspectives. *J Mycol Med*. 2020 Sep;30(3):101007.
6. Manesh A, Rupali P, Sullivan MO, Mohanraj P, Rupa V, George B, et al. Mucormycosis-A clinicoepidemiological review of cases over 10 years. *Mycoses*. 2019 Apr;62(4):391–8.
7. Song G, Liang G, Liu W. Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China. *Mycopathologia*. 2020 Jul 31;1–8.
8. Chikley A, Ben-Ami R, Kontoyiannis DP. Mucormycosis of the Central Nervous System. *J Fungi (Basel)*. 2019 Jul 8;5(3):59.
9. Al Hassan F, Aljahli M, Molani F, Almomen A. Rhino-orbito-cerebral mucormycosis in patients with uncontrolled diabetes: A case series. *Int J Surg Case Rep*. 2020 Jul 15;73:324–7.
10. Moorthy A, Gaikwad R, Krishna S, Hegde R, Tripathi KK, Kale PG, et al. SARS-CoV-2, Uncontrolled Diabetes and Corticosteroids—An Unholy Trinity in Invasive Fungal Infections of the Maxillofacial Region? A Retrospective, Multi-centric Analysis. *J Maxillofac Oral Surg*. 2021 Mar 6;1–8.